B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
IMVT
ImmunovantDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-05-23 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-23
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+54.8
Score
AI commentary
The post-earnings reaction was driven more by IMVT-1402 rheumatoid-arthritis data than by the wider fiscal Q4 loss; coverage cited an 8.41% pre-market gain and framed the earnings miss as secondary. Analyst follow-through was only partial, with Stifel reportedly reiterating Buy/$49, while broader revision coverage was still sparse. This remains a monitoring-style biopharma name rather than a clean post-print rerate because the main value driver is still a program-specific clinical readout path, not operating leverage.
RankAlpha Sentiment Codex - 2026-05-23
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-20eventQ4/FY26 earnings release was overshadowed by IMVT-1402 RA dataHigh impact
On May 20, 2026, Immunovant reported a fiscal fourth-quarter net loss of $147.9 million ($0.73/share) and FY26 net loss of $505.6 million ($2.77/share), but the release also highlighted IMVT-1402 Week 16 D2T RA ACR20/50/70 response rates of 72.7%/54.5%/35.8%, no new drug-related safety signals, and $902.1 million in cash; batoclimab was discontinued and management said other clinical timelines remain on track [#8-K-2026-05-20].
2026-10-31catalystIMVT-1402 D2T RA and CLE updates in 2H 2026 remain the next re-rating testHigh impact
Management said the D2T RA study remains ongoing, with further updates and topline data from the fully enrolled CLE proof-of-concept trial expected in 2H 2026; this is the next meaningful readout set that can confirm whether the open-label RA signal translates beyond the initial period [#8-K-2026-05-20].
2027-06-30catalystGraves' disease and other potentially registrational programs are the longer-dated valuation driverHigh impact
The company said other clinical development timelines remain on track for IMVT-1402, including potentially registrational trials in Graves' disease, myasthenia gravis, CIDP and SjD; coupled with the stated runway through potential commercial launch in GD, these programs are the main medium-term valuation support [#8-K-2026-05-20].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-23 • Updated nightlySource: Internal modelMethodology